Aetna, Hartford, Connecticut.
Facing Our Risk of Cancer Empowered, Inc (FORCE), Tampa, Florida.
JAMA Oncol. 2015 Dec;1(9):1251-60. doi: 10.1001/jamaoncol.2015.3048.
BRCA genetic testing has substantial public health impact, yet little is known of the real-world experiences of the more than 100 000 Americans undergoing testing annually.
To identify factors associated with use of BRCA testing, assess whether delivery of genetic counseling and testing services adheres to professional guidelines, and measure the impact on patient-reported outcomes.
DESIGN, SETTING, AND PARTICIPANTS: The American BRCA Outcomes and Utilization of Testing (ABOUT) Study analyzed data from a consecutive national series of 11 159 women whose clinicians ordered BRCA testing between December 2011 and December 2012. Aetna mailed recruitment information across the United States to commercial health plan members whose clinicians had ordered BRCA testing. A total of 3874 women (34.7%) completed questionnaires. Deidentified clinician-reported data from all respondents and a random sample of 2613 nonrespondents were also analyzed.
The proportion of eligible participants who met testing criteria and respondents' report of receiving genetic counseling by a genetics clinician and its association with BRCA knowledge, understanding, and satisfaction were assessed.
Among 3628 women respondents whose clinicians ordered comprehensive BRCA testing, most were white non-Hispanic (2502 [69.0%]), college educated (2953 [81.4%]), married (2751 [75.8%]), and had higher incomes (2011 [55.4%]). Approximately 16.4% (596) did not meet testing criteria. Mutations were identified in 161 (5.3%) of these women who received comprehensive testing. Only 1334 (36.8%) reported receiving genetic counseling from a genetics clinician prior to testing; the lowest rates (130 [12.3%]) were among patients of obstetrician/gynecologists. The most commonly reported reason for not receiving this clinical service was lack of clinician recommendation. Those who received it demonstrated greater knowledge about BRCA (mean score difference adjusted for demographics and clinician specialty, β = 0.99 [95% CI, 0.83-1.14]; P < .001) and expressed greater understanding (β = 0.47 [95% CI, 0.41-0.54]; P < .001) and satisfaction (β = 2.21 [95% CI, 1.60-2.81]; P < .001).
Despite improved patient knowledge, understanding, and satisfaction among patients who receive genetic counseling provided by a genetics clinician, as well as multiple guidelines emphasizing the importance of genetic counseling, most US women undergoing BRCA genetic testing do not receive this clinical service. Lack of physician recommendation is the most commonly reported reason. These findings demonstrate important gaps in clinical genetics services. Recently mandated coverage of genetic counseling services as a preventive service without patient cost sharing should contribute to improving clinical genetics services and associated outcomes in the future.
BRCA 基因检测对公共健康有重大影响,但对于每年接受检测的 10 万多美国人的实际体验,我们知之甚少。
确定与 BRCA 检测使用相关的因素,评估遗传咨询和检测服务的提供是否符合专业指南,并衡量对患者报告结果的影响。
设计、设置和参与者:美国 BRCA 结果和检测利用(ABOUT)研究分析了连续的全国范围内 11159 名女性的数据,她们的临床医生在 2011 年 12 月至 2012 年 12 月期间开了 BRCA 检测。Aetna 向美国各地的商业健康计划成员邮寄了招募信息,这些成员的临床医生曾开了 BRCA 检测。共有 3874 名女性(34.7%)完成了问卷调查。还分析了所有应答者的匿名临床医生报告数据和 2613 名非应答者的随机样本。
评估符合检测标准的合格参与者比例,以及应答者报告接受遗传学临床医生的遗传咨询及其与 BRCA 知识、理解和满意度的关联。
在 3628 名接受全面 BRCA 检测的女性应答者中,大多数是白人非西班牙裔(2502 [69.0%]),受过大学教育(2953 [81.4%]),已婚(2751 [75.8%]),收入较高(2011 [55.4%])。约 16.4%(596)不符合检测标准。在接受全面检测的这些女性中,有 161 人(5.3%)发现了突变。只有 1334 名(36.8%)报告在检测前接受过遗传学临床医生的遗传咨询;最低的比率(130 [12.3%])是妇产科医生的患者。不接受这项临床服务的最常见原因是缺乏临床医生的推荐。接受咨询的患者对 BRCA 的了解程度更高(调整人口统计学和临床医生专业后,平均得分差异为 0.99 [95% CI,0.83-1.14];P <.001),理解程度更高(β = 0.47 [95% CI,0.41-0.54];P <.001),满意度更高(β = 2.21 [95% CI,1.60-2.81];P <.001)。
尽管接受遗传学临床医生提供的遗传咨询的患者的知识、理解和满意度有所提高,而且多项指南都强调了遗传咨询的重要性,但大多数接受 BRCA 基因检测的美国女性并未接受这项临床服务。缺乏医生推荐是最常见的原因。这些发现表明临床遗传学服务存在重要差距。最近规定的遗传咨询服务作为预防服务,不向患者收取费用,这应该有助于改善未来的临床遗传学服务和相关结果。